3.42
0.04 (1.18%)
| Previous Close | 3.38 |
| Open | 3.27 |
| Volume | 4,367 |
| Avg. Volume (3M) | 188,941 |
| Market Cap | 5,617,576 |
| Price / Earnings (Forward) | 21.83 |
| Price / Sales | 10.31 |
| Price / Book | 0.190 |
| 52 Weeks Range | |
| Earnings Date | 7 Aug 2025 - 11 Aug 2025 |
| Operating Margin (TTM) | -34,814.94% |
| Diluted EPS (TTM) | 0.660 |
| Quarterly Revenue Growth (YOY) | -58.70% |
| Total Debt/Equity (MRQ) | 4.70% |
| Current Ratio (MRQ) | 1.05 |
| Operating Cash Flow (TTM) | -7.03 M |
| Levered Free Cash Flow (TTM) | -6.06 M |
| Return on Assets (TTM) | -14.99% |
| Return on Equity (TTM) | -35.92% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Pharmaceutical Retailers (US) | Mixed | Mixed |
| Pharmaceutical Retailers (Global) | Mixed | Mixed | |
| Stock | Scienture Holdings, Inc. | Mixed | - |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Relative Valuation | NA |
| Financial Health | -2.5 |
| AI Insight | NA |
| Weighted Average | -0.21 |
Select this tab to load the latest available analysis.
|
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders. |
|
| Sector | Healthcare |
| Industry | Pharmaceutical Retailers |
| Investment Style | Small Value |
| % Held by Insiders | 32.59% |
| % Held by Institutions | 1.35% |
No data within this time range.
No data within this time range.
| Ex Date | Announcement Date | Payment Date | Details |
|---|---|---|---|
| 19 Jul 2024 | 08 Jul 2024 | 24 Jul 2024 | 1.5 Cash |
| 25 Mar 2024 | 28 Feb 2024 | 22 Mar 2024 | 8 Cash |
Annual Dividend Yield
| Year | Annual Dividend ($) | Frequency/Year | Yield % |
|---|---|---|---|
| 2024 | 9.50 | 2 | 157.03 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |